Dr. Lukas Scheibler is the Chief Research & Development Officer at Tavo Biotherapeutics and is a seasoned R&D leader with over two decades of experience in ophthalmology and pharmaceutical innovation. He most recently served as Chief Innovation Officer at Apellis, where he oversaw all research and development activities from discovery through human proof of concept. Before joining Apellis, Lukas was Head of Clinical Development at Alcon, where he led the global clinical trial strategy and execution across a broad portfolio of ophthalmic therapies. He began his career at Novartis in ophthalmology R&D, where he played a central role in the in-licensing and European approval of Lucentis, one of the first anti-VEGF therapies to transform retinal disease treatment. Lukas holds a PhD from the University of Lausanne and completed postdoctoral training at Harvard Medical School. He is recognized for combining scientific rigor with strategic insight to accelerate innovation and deliver impactful therapies to patients.